Seven Eight Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,860
| Closed | -$3.13M | – | 3 |
|
|
2024
Q3 | $3.13M | Buy |
15,860
+12,779
| +415% | +$2.38M | 0.28% | 87 |
|
|
2024
Q2 | $528K | Sell |
3,081
-83
| -3% | -$13.7K | 0.06% | 506 |
|
|
2024
Q1 | $576K | Buy |
+3,164
| New | +$545K | 0.06% | 429 |
|
|
2023
Q4 | – | Sell |
-14,665
| Closed | -$2.19M | – | 595 |
|
|
2023
Q3 | $2.19M | Sell |
14,665
-33,739
| -70% | -$4.95M | 0.26% | 102 |
|
|
2023
Q2 | $6.52M | Buy |
+48,404
| New | +$7.1M | 1.08% | 6 |
|
|
2022
Q2 | – | Sell |
-17,183
| Closed | -$2.79M | – | 369 |
|
|
2022
Q1 | $2.79M | Buy |
17,183
+9,533
| +125% | +$1.38M | 0.37% | 80 |
|
|
2021
Q4 | $1.04M | Buy |
7,650
+4,623
| +153% | +$546K | 0.19% | 165 |
|
|
2021
Q3 | $327K | Sell |
3,027
-16,226
| -84% | -$1.85M | 0.03% | 492 |
|
|
2021
Q2 | $2.17M | Buy |
+19,253
| New | +$2.17M | 0.3% | 83 |
|
|
2020
Q4 | – | Sell |
-6,813
| Closed | -$597K | – | 386 |
|
|
2020
Q3 | $597K | Buy |
+6,813
| New | +$641K | 0.13% | 306 |
|
|
2020
Q1 | – | Sell |
-35,473
| Closed | -$3.14M | – | 438 |
|
|
2019
Q4 | $3.14M | Buy |
+35,473
| New | +$2.94M | 0.17% | 186 |
|
|
2019
Q3 | – | Sell |
-205,958
| Closed | -$15M | – | 574 |
|
|
2019
Q2 | $15M | Buy |
205,958
+189,200
| +1,129% | +$14.9M | 0.79% | 18 |
|
|
2019
Q1 | $1.35M | Buy |
+16,758
| New | +$1.37M | 0.07% | 314 |
|
|
2018
Q3 | – | Sell |
-81,658
| Closed | -$7.57M | – | 553 |
|
|
2018
Q2 | $7.57M | Sell |
81,658
-47,700
| -37% | -$4.66M | 0.53% | 59 |
|
|
2018
Q1 | $12.2M | Buy |
+129,358
| New | +$14.2M | 1.01% | 6 |
|
|
2017
Q4 | – | Sell |
-84,858
| Closed | -$7.54M | – | 436 |
|
|
2017
Q3 | $7.54M | Buy |
84,858
+74,400
| +711% | +$5.66M | 0.92% | 9 |
|
|
2017
Q2 | $758K | Buy |
+10,458
| New | +$703K | 0.11% | 250 |
|
|
2017
Q1 | – | Sell |
-8,558
| Closed | -$536K | – | 502 |
|
|
2016
Q4 | $536K | Buy |
+8,558
| New | +$522K | 0.11% | 272 |
|
|
2015
Q3 | – | Sell |
-10,377
| Closed | -$697K | – | 511 |
|
|
2015
Q2 | $697K | Buy |
+10,377
| New | +$677K | 0.82% | 11 |
|
|
2015
Q1 | – | Sell |
-5,476
| Closed | -$358K | – | 478 |
|
|
2014
Q4 | $358K | Buy |
+5,476
| New | +$345K | 0.6% | 44 |
|
Other funds holding ABBV
Seven Eight Capital's ABBV Position: Q4 2024 in Review
Seven Eight Capital sold out of AbbVie (ABBV) in Q4 2024, closing a stake of 15,860 shares — an estimated $3.13M sold.
Seven Eight Capital first reported a position in ABBV in Q4 2014 and held it in 20 quarters. The position peaked at $15M in Q2 2019. 3,745 funds tracked by Wall St. Rank hold ABBV as of Q4 2024.
- Seven Eight Capital reported no remaining AbbVie position as of Q4 2024 after selling out during the quarter.
- Seven Eight Capital sold 15,860 AbbVie shares in Q4 2024, an estimated $3.13M.
- Seven Eight Capital first reported a position in AbbVie in Q4 2014 and held it in 20 quarters.
- Seven Eight Capital's AbbVie position peaked at $15M in Q2 2019.
- 3,745 funds tracked by Wall St. Rank held AbbVie as of Q4 2024.
Based on Seven Eight Capital's 13F filing for Q4 2024.